🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Cryo-Cell International, Inc. CCEL PHARMA

Healthcare · Medical Care Facilities · United States
https://www.cryo-cell.com
Company Profile ↓
$4.26
-6.37% 1Y
Mkt Cap$34.35M
P/E-13.74
P/B-1.87
Div. Yield17.19%
52W High$4.93
52W Low$2.89
Book Value$-2.20
EPS (TTM)$-0.31

Company Overview

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Why Investors Should Care

Healthy Margins

Operating margin of 15.4% supports profitability.

Dividend Income

Offers a dividend yield of 17.19%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Nov 2025 Revenue of $31.57M (-1.3% YoY); net profit $-2.43M.
  • Trailing 12 Months Year-on-year growth — revenue -1.9%, earnings +72.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 4.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:4.19%
1 Year:-1.90%

Compounded Profit Growth

5 Years:-
1 Year:72.10%

Stock Price Performance

1 Year:-6.37%
6 Months:+33.96%
3 Months:+16.08%
1 Month:+18.33%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 67% of range
$2.89 $4.93
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.43 · Neutral
Price Performance
1M+18.33%
3M+16.08%
6M+33.96%
1Y-6.37%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Attractive dividend yield of 17.19%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-13.74
Industry PE
24.83
Forward P/E
213.00
PEG Ratio
1.34
Book Value
$-2.20
Price to Book
-1.87
P/S
1.06
EV/EBITDA
46.08
Dividend Yield
17.19%

Growth (CAGR)

Revenue 5Y
4.19%
Profit 5Y
-
Revenue (YoY)
-1.90%
Earnings (YoY)
72.10%

Profitability & Returns

ROCE
11.54%
ROE
13.06%
ROA
-0.10%
Profit Margin
-7.92%
Op Margin
15.40%
Gross Margin
63.93%
EPS (Latest Qtr)
$0.07
EPS (TTM)
$-0.31

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
0.63
Current Ratio
0.71
Debt
$8.96M
Total Assets
$60.71M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
34.59%
Chg in Prom Hold
-7.44%
FII / Inst Holding
13.72%
Chg in FII Hold
0.37%

Financial Snapshot

Enterprise Value
$34.35M
Total Revenue (TTM)
$31.13M
EBITDA
$871.17K
Free Cash Flow
$1.52M
Operating Cash Flow
$6.32M
Shares Outstanding
8.06M
Gross Margin
63.93%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CCEL Cryo-Cell International, Inc. PHARMA 4.26 -13.74 $34.35M 17.19% 11.54% 13.06% 4.19% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Feb 2014May 2014Aug 2014Feb 2015May 2015Aug 2015Feb 2016May 2016Aug 2016Feb 2017May 2017Aug 2017Feb 2018May 2018Aug 2018Feb 2019May 2019Aug 2019Feb 2020May 2020Aug 2020Feb 2021May 2021Aug 2021Feb 2022May 2022Aug 2022Feb 2023May 2023Aug 2023Feb 2024May 2024Aug 2024Nov 2024Feb 2025May 2025Aug 2025Nov 2025Feb 2026May 2026
Revenue 5.32M4.89M4.94M4.84M5.01M5.44M5.15M5.77M6.33M5.78M6.24M6.90M6.23M6.53M--------------------7.97M7.93M-7.84M7.68M7.78M
Cost of Revenue ----------------------------------1.98M1.86M-1.73M1.66M1.68M
Gross Profit ----------------------------------5.98M6.07M-6.11M6.03M6.10M
Operating Expenses ----------------------------------4.93M4.58M-5.72M5.26M4.90M
Operating Income 804.52K562.33K428.96K625.19K602.09K1.26M156.42K882.38K-1.06M1.12M1.19M1.45M987.14K1.15M920.12K853.66K496.56K1.99M1.25M1.75M2.48M1.24M2.00M1.60M1.47M1.19M954.31K1.68M1.03M1.16M821.22K1.39M1.39M-1.06M1.49M1.90M392.05K765.13K1.20M
EBITDA ----------------------------------1.37M1.47M--3.82M875.02K1.61M
Interest Expense ----------------------------------494.96K551.13K-481.95K462.71K441.92K
Pretax Income ----------------------------------533.72K575.10K--4.63M70.31K827.78K
Tax Provision ----------------------------------250.86K219.32K--814.54K23.20K273.19K
Net Income 397.11K215.77K236.57K286.17K210.03K7.83M-122.94K637.13K-2.64M486.92K496.94K652.02K-2.53M539.51K244.98K275.88K53.67K1.12M686.97K953.34K784.47K693.59K1.17M856.49K832.05K634.72K466.82K766.81K220.98K680.56K556.24K655.79K1.05M-282.86K355.79K749.41K-3.82M47.11K554.59K
Diluted EPS 0.040.020.020.030.020.80-0.010.07-0.350.070.060.08-0.360.070.030.030.010.130.080.120.100.080.140.100.100.070.060.090.030.080.070.080.13-0.030.040.09-0.010.07
R&D Expense 14.37K18.32K17.85K11.99K10.53K9.95K8.68K11.99K13.78K14.62K8.84K22613.41K29.28K22.23K5.88K4.96K2.44K5.72K9.82K1.25K6.19K3.24K10.00K147.22K80.90K80.27K78.83K304.68K344.13K502.89K241.09K193.93K-98.14K131.71K61.62K-65.76K99.78K

Profit & Loss (Annual)

Figures in USD.

Metric Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Revenue 17.76M17.92M17.97M18.99M20.13M21.09M23.13M25.38M29.22M31.82M31.15M-30.34M31.34M31.99M31.57M
Cost of Revenue ------------8.79M8.39M7.95M7.38M
Gross Profit ------------21.54M22.95M24.04M24.19M
Operating Expenses ------------17.08M19.46M20.25M19.35M
Operating Income 3.35M-276.74K-1.71M1.70M1.98M2.93M433.59K5.01M5.19M5.06M7.66M-4.46M3.49M3.79M4.84M
EBITDA ------------6.65M-10.42M5.69M1.10M
Interest Expense ------------1.52M1.24M1.86M2.07M
Pretax Income ------------3.32M-13.36M2.80M-2.34M
Tax Provision ------------547.54K-3.84M2.40M92.23K
Net Income 3.46M-2.10M-6.31M27.44K553.62K8.11M-1.32M2.32M-854.82K2.29M3.62M-2.77M-9.52M402.10K-2.43M
Diluted EPS 0.29-0.18-0.560.000.050.83-0.160.30-0.110.270.45-0.33-1.150.05-0.30
R&D Expense 132.99K184.05K109.64K36.17K64.37K45.78K53.10K41.16K91.84K30.14K23.85K49.87K384.79K1.17M1.24M376.26K

Balance Sheet (Annual)

Figures in USD.

Metric Nov 2009Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Total Assets -18.09M19.47M12.33M11.50M10.21M19.50M19.54M23.91M42.39M42.89M46.20M60.66M64.89M61.22M64.68M61.73M
Total Equity -4.69M-1.00M-2.46M-9.00M-9.27M-10.73M-4.96M-15.41M-12.50M-8.91M-6.95M-2.67M4.18M-1.52M-11.03M-13.22M-18.61M
Cash & Equivalents 6.85M8.37M6.31M2.68M3.93M3.28M4.15M3.50M6.28M6.04M6.54M10.36M8.26M1.70M406.07K560.96K319.03K
Long Term Debt -3.75M2.85M2.30M2.30M2.30M2.30M1.43M1.43M1.43M8.96M5.94M1.90M8.73M8.60M8.48M8.35M
Total Liabilities ------24.46M34.95M36.41M51.30M49.84M48.87M56.48M66.41M72.25M77.89M80.33M
Current Liabilities -8.26M10.56M10.66M9.81M9.13M10.42M13.11M13.94M15.43M15.43M16.41M21.07M19.48M20.86M21.60M19.79M

Cash Flows (Annual)

Figures in USD.

Metric Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Operating Cash Flow 2.34M819.12K360.90K821.98K---5.72M5.33M6.29M8.47M7.93M8.57M8.92M6.01M5.48M
Investing Cash Flow -819.62K-2.96M962.36K1.15M---93.03K-11.28M-662.29K357.49K-6.95M-15.28M-8.14M-4.88M-975.33K
Financing Cash Flow -80.94K-4.95M-723.67K----3.03M5.71M-5.13M-5.00M-3.07M147.86K-2.07M-979.12K-4.75M
Capital Expenditure -398.90K-505.71K-133.54K-349.78K-120.52K-108.48K-342.98K-98.33K-446.16K-662.29K-99.96K-1.83M-12.17M-6.84M-2.40M-230.47K
Free Cash Flow 1.94M313.41K227.36K472.20K---5.62M4.89M5.63M8.37M6.09M-3.60M2.08M3.61M5.25M
Share Buybacks --1.70M738.62K2.67M3.21M10.81M446.62K-992.24K-249.38K1.82M799.04K1.42M169.50K

Ratios (Annual)

Figures in %.

Metric Nov 2010Nov 2011Nov 2012Nov 2013Nov 2014Nov 2015Nov 2016Nov 2017Nov 2018Nov 2019Nov 2020Nov 2021Nov 2022Nov 2023Nov 2024Nov 2025
Gross Margin % ------------71.0%73.2%75.2%76.6%
Operating Margin % 18.8%-1.5%-9.5%9.0%9.8%13.9%1.9%19.7%17.8%15.9%24.6%-14.7%11.1%11.8%15.3%
Net Margin % 19.5%-11.7%-35.1%0.1%2.8%38.4%-5.7%9.1%-2.9%7.2%11.6%-9.1%-30.4%1.3%-7.7%
ROE % -345.8%85.2%70.1%-0.3%-5.2%-163.3%8.6%-18.5%9.6%-32.9%-136.0%--181.8%86.3%-3.0%13.1%
ROCE % 34.0%-3.1%-102.7%100.7%183.0%32.3%6.7%50.2%19.2%18.4%25.7%-9.8%8.6%8.8%11.5%

Shareholding Pattern

Insiders
34.59%
Institutions
13.72%
Public Float
20.97%

Top Institutional Holders

#Holder% HeldSharesValue
1 SFI Advisors, LLC 1.46% 165.30K $727.32K
2 Vanguard Capital Management LLC 1.46% 164.98K $725.89K
3 MassMutual Private Wealth & Trust, FSB 0.98% 111.03K $488.55K
4 Geode Capital Management, LLC 0.41% 46.27K $203.60K
5 Vanguard Fiduciary Trust Co 0.21% 23.35K $102.72K
6 FMR, LLC 0.18% 20.00K $88.00K
7 Susquehanna International Group, LLP 0.12% 14.06K $61.88K
8 Blackrock Inc. 0.06% 6.70K $29.46K
9 Osaic Holdings Inc. 0.02% 2.50K $11.00K
10 Morgan Stanley 0.01% 605 $2.66K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CCEL

Google News Wed, 15 Jul 2026

Cryo-Cell Intl Inc (CCEL) Debt 2025: $8.4M, down 1.5% - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE0wcVhNOGltUHlfNE05SWF4OEF4Ylg0ei1HeHAzV1lySFNpd3E0SnBsMnVJSUpoTDd2NU1McDYxbUtEY1hyZmZSSGtPMUI1RUJ2MXV0QmJDd2tmcTFT?oc=5" target="_blank">Cryo-Cell Intl Inc (CCEL) Debt 2025: $8.4M,…

Google News Wed, 12 Aug 2026

Cryo-Cell International (CCEL) Holds Flat at $3.51 Amid Tight Trading Range - Sweep Order Flow - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPTS0xSjEySVhMcHptdHRSMnhLY0NYc0p6cWhjbHF4Uy04TDd2WHFqc1JNZGMySUxMODllX2N6bEF1ejhTMXlmR1huVE5xZDYyR2RkN3RSV0hqdWhjYlBRbnk4WGsxa0FmT29xOW5QOWZ3b1kzSlk2SDZwazdMaGZYc3EzV2hQMFlBVGZKeD…

Google News Sun, 24 Mar 2024

symbol__ Stock Quote Price and Forecast - CNN

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9GQS1RR2t2V2FQNFBzMjg3ZFdOdzJHM2ZCRUQ3akMwTTVCRWdpUTJDdTNtVm04VUJuWm12M0R3ZkR6ZWNtUVM2eHAySDlCZGJI?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a>&nbsp;&nbsp;<fon…

Google News hu, 26 Mar 2026

Eric Shahinian Takes Activist Stake at Cryo-Cell International with 5.3% Stake - tradingview.com

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQQVZma0VuNENaT1VBb04tQzZFUkNEOXlPZHUxT2tLWXQ0Nk9DUmVrOF9BaW5rZzlJUXdGcnFrYUc0UkYtTjRfaXZtRjY0eEFJTE9JWV9rNm9LRVItcG1fT2NQYmlfbkRhUmdpbmd5RUVJVmd2bUxSMU54UUZvcjhYWlpzeGhldW5wZmFYVj…

Google News Fri, 31 Jul 2026

Cryo-Cell International Inc (CCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE5JTXIwOHRvUlJKOUtROFg2THJUU2VVNTY5dGROYkUzblh5NFZLZlpKdWd6dlRmQ2ZkWERTU1dDLUZxeURJSm0xM19FX1ViazMtUFpKR3FVSlFCdktBVm11UEk2VkJvQXJpdEREYkZNVFZzUQ?oc=5" target="_blank">Cryo-Cell Int…

Google News Sun, 26 Jul 2026

Cryo-Cell International (CCEL) Slips Slightly, Holds Above Key Support at $3.29 - Force Index - dars.gov.et

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOd1VmQUo0cS1ic3JEczRRS0s3M2Y4WHB3cU02dENrVl9yVkV3di0xUmtTc2pHLTF0U2EtandERnZVOG5OdVlabFEyWFpkd2VsQzk5cGZPZ0dBZk1hazJPR3ZHUERiMFdOTVNtdDVXcGxXa29NQ3hSUVpkYjZQdWltWnhLdE5RN3c1NGpXQk…

CCEL — Frequently Asked Questions

What is the current share price of Cryo-Cell International, Inc. (CCEL)?

As of 2026-09-19 21:16 PDT, Cryo-Cell International, Inc. (CCEL) trades at $4.26 on NYSE American. Its 52-week range is $2.89 to $4.93.

What is the market capitalisation of CCEL?

Cryo-Cell International, Inc. (CCEL) has a market capitalisation of $34.35M on NYSE American.

What is the P/E ratio of CCEL?

CCEL trades at a trailing price-to-earnings (P/E) ratio of -13.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -1.87.

Does CCEL pay a dividend?

Cryo-Cell International, Inc. (CCEL) currently offers a dividend yield of 17.19%.

What is the return on equity (ROE) of CCEL?

CCEL has a return on equity (ROE) of 13.06%. Its return on capital employed (ROCE) is 11.54%.

Is CCEL a good stock to buy?

This page provides a data-driven analysis of Cryo-Cell International, Inc. (CCEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space